Stockscreener 앱 받기
0.5401
0.95%
0.0051
시간 외 거래:
.52
-0.0201
-3.72%
전일 마감가:
$0.535
열려 있는:
$0.5416
하루 거래량:
75,561
Relative Volume:
0.18
시가총액:
$22.43M
수익:
$9.57M
순이익/손실:
$-43.11M
주가수익비율:
-0.3234
EPS:
-1.67
순현금흐름:
$-49.54M
1주 성능:
-8.44%
1개월 성능:
+18.47%
6개월 성능:
-27.44%
1년 성능:
-50.68%
1일 변동 폭
$0.5228
$0.5491
1주일 범위
$0.4963
$0.5898
52주 변동 폭
$0.4112
$5.95
스프루스 바이오 Stock (SPRB) Company Profile
명칭
Spruce Biosciences Inc
전화
(415) 655-4168
주소
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
스프루스 바이오 Stock (SPRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | The Benchmark Company | Speculative Buy |
| 2021-11-16 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | 개시 | H.C. Wainwright | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2020-11-03 | 개시 | SVB Leerink | Outperform |
모두보기
스프루스 바이오 주식(SPRB)의 최신 뉴스
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Spruce Biosciences faces Nasdaq delisting notice By Investing.com - Investing.com South Africa
Spruce Biosciences faces Nasdaq delisting notice - Investing.com
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference - StockTitan
Global Adrenogenital Syndrome Treatment Market to Reach USD 22.08 Billion in 2033, Driven by New The - PharmiWeb.com
Congenital Adrenal Hyperplasia Clinical Trials 2024: FDA Approvals, Companies, Medication, Treatment Market, Therapies, ROA and MOA by DelveInsight | Becton, Dickinson and Company, Cook Medical, MORE - Barchart
Floyd Mayweather Jr buying $402M Black Spruce portfolio - Yahoo Finance
Congenital Adrenal Hyperplasia (CAH) Therapeutic Market 2024 - openPR
Ambev S.A. (NYSE:ABEV) Given Average Rating of “Hold” by Brokerages - Defense World
Daily Progress: Spruce Biosciences Inc (SPRB) Drop -5.56, Closing at 0.43 - The Dwinnex
The Significance of Moving Averages in Spruce Biosciences Inc Inc. (SPRB) Price Performance - The InvestChronicle
A closer look at Spruce Biosciences Inc (SPRB)’s stock price trends - US Post News
North Carolina town that produces quartz needed for tech products is devastated by Helene - Yahoo Finance
Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock - Investing.com
Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock By Investing.com - Investing.com UK
Neurocrine Biosciences's Crinecerfont is Set to Transform the Congenital Adrenal Hyperplasia Treatment Market | DelveInsight - PR Newswire
Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily
Spruce Biosciences Inc (SPRB) expanding its growth trajectory ahead - SETE News
Spruce Biosciences Inc [SPRB] stock for 350,951 USD was sold by Novo Holdings A/S - Knox Daily
Spruce Biosciences Inc’s results are impressive - US Post News
Financial Fitness Check: Examining Spruce Biosciences Inc (SPRB)’s Key Ratios - The Dwinnex
Checking in on Spruce Biosciences Inc (SPRB) after recent insiders movement - Knox Daily
Life Time Group Holdings Inc (LTH) gets rating Initiated from Craig Hallum - Knox Daily
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Potential Price Increase for Spruce Biosciences Inc (SPRB) After Recent Insider Activity - Knox Daily
SPRBSpruce Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
An Inquiry Has Been Launched Into Whether Spruce Biosciences Inc. Violated Securities Regulations And Stockholders Are Encouraged To Assist - StockTitan
Spruce Biosciences Inc (SPRB) Becoming More Attractive for Investors - Knox Daily
SPRB (Spruce Biosciences) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
SPRB (Spruce Biosciences) Dividends per Share : $0.00 (TTM As of Jun. 2024) - GuruFocus.com
Spruce Power Holding Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.17 profit in 2Q 2023) - Yahoo Finance
Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Beats Expectations By $0.10 EPS - Defense World
What technical indicators reveal about SPRB stock - US Post News
Spruce Biosciences’ (SPRB) Sector Perform Rating Reaffirmed at Royal Bank of Canada - Defense World
Spruce Biosciences Inc [SPRB] Insider Activity: An Update for Investors - Knox Daily
Ratios Reveal: Breaking Down Spruce Biosciences Inc (SPRB)’s Financial Health - The Dwinnex
SPRB stock touches 52-week low at $0.42 amid market challenges - Investing.com Australia
SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - Manchestertimes
Is Spruce Biosciences Inc (NASDAQ: SPRB) A Good Investment Now? - Stocks Register
Taking a look at what insiders are doing to gauge the Spruce Biosciences Inc (SPRB)’s direction - Knox Daily
Have you been able to find a good deal on Spruce Biosciences Inc’s shares? - US Post News
Market Recap: Spruce Biosciences Inc (SPRB)’s Negative Momentum, Closing at 0.45 - The Dwinnex
Nothing is Better Than Spruce Biosciences Inc (SPRB) stock at the moment - SETE News
Analysts review Spruce Biosciences Inc’s rating - Knox Daily
Ratio Revelations: Spruce Biosciences Inc (SPRB)’s Financial Metrics in the Spotlight - The Dwinnex
SPRB stock touches 52-week low at $0.5 amid market challenges - Investing.com
Spruce Biosciences Inc [SPRB] Investment Appeal on the Rise - Knox Daily
Investors With Losses Are Urged To Initiate Dialogue As Spruce B - WICZ
Investors With Losses Are Urged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm - AccessWire
스프루스 바이오 (SPRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
스프루스 바이오 주식 (SPRB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | 10% Owner |
Mar 18 '24 |
Sale |
0.77 |
842,020 |
647,008 |
3,968,000 |
| Novo Holdings A/S | 10% Owner |
Mar 19 '24 |
Sale |
0.76 |
593,000 |
447,715 |
3,375,000 |
| Novo Holdings A/S | 10% Owner |
Mar 20 '24 |
Sale |
0.73 |
359,979 |
264,081 |
3,015,021 |
| Novo Holdings A/S | 10% Owner |
Mar 14 '24 |
Sale |
0.89 |
1,912,316 |
1,698,902 |
4,810,020 |
| Charlton Ralph William III | Chief Medical Officer |
Dec 15 '23 |
Option Exercise |
0.00 |
31,750 |
0 |
56,992 |
| Gharib Samir M. | President & CFO |
Dec 15 '23 |
Option Exercise |
0.00 |
112,250 |
0 |
204,403 |
| Szwarcberg Javier B. | Chief Executive Officer |
Dec 15 '23 |
Option Exercise |
0.00 |
111,000 |
0 |
145,705 |
2.02%
0.47%
자본화:
|
볼륨(24시간):